Tijdens dit wetenschappelijk programma komen laatste klinische onderzoeken en ontwikkelingenen op het gebied van FL (follicular lymphoma) aan bod. De bijeenkomst bestaat uit een combinatie van presentaties van internationale experts binnen het vakgebied, interactieve paneldiscussies, het beantwoorden van stemvragen en de mogelijkheid voor vragen en discussies vanuit het publiek.

In de uitnodiging wordt de bijeenkomst als volgt omschreven:

With recent advances in oncology and especially in follicular lymphoma (FL), we are now on the beginning of a new era. Better understanding of the biology of FL have led to the rapid development of several diagnostic and therapeutic innovations and are finding its way into daily clinical practice.

To give an overview of the wealth of new data and to better understand these advances in oncology, we would like to invite you to join and participate in a dynamic and informative symposium “How to identify and treat the high-risk FL patient?”.

In previous editions, the symposium was focused around novel insights regarding the biology of B-cell malignancies (2015) and high-risk CLL (2016). This year, well known international and local experts will present and discuss the latest developments in both diagnostic as well as therapeutic approaches in high-risk FL. The symposium will cover a range of topics, from understanding the pathobiology of high-risk FL, to the practical guidance of treatment options in (transformed) FL, all in order to address the question: “How to identify and treat the high-risk FL patient?”

The symposium will be led by Dr. Josée Zijlstra, associate professor of  Hematology,  leader of the theme Imaging of the Cancer Center Amsterdam, actively involved in HOVON and GHSG Lymphoma trials, and chair of the Imaging working group at the Haemato Oncology Foundation for Adults in the Netherlands (HOVON).

We look forward to welcoming you to what will surely be an informative symposium and a fantastic learning experience.

“Advances in Oncology”: A series of cross-country collaborative educational symposia to educate (hemato)-oncologists on recent advances in oncology.